Telehealth

As Canada ages, one annual pitch contest reveals its true intent: not just to award ideas, but to strategically build a national AgeTech ecosystem.

In a bold strategic move, ivari is bundling on-demand healthcare with life insurance, signaling a market shift from passive protection to proactive wellness.

A $4M grant for a Parkinson's drug isn't just charity; it's a strategic bet on a new era of medicine, where philanthropy acts as the catalyst for the next big cure.

Sun Life's Jacques Goulet brings a background in risk management and a proven record of philanthropic impact to his new role as Chair of the MHIF.

Nancy Torres analyzes Héma-Québec's summer tour, revealing a sophisticated strategy to combat supply chain risks, secure plasma independence, and diversify its donor base.

One year in, the Facial Pain Registry has gathered data from 740 patients, creating an unprecedented resource to fight one of medicine's most misunderstood conditions.

A new partnership between Daybreak and VHSS isn't just about a new device; it’s a durable model for delivering resilient healthcare solutions to veterans.

A new app, born from its founder's personal health battle, challenges the 'no pain, no gain' ethos of digital wellness with a flexible, empathetic model.

Beacon Biosignals is merging AI-driven brain monitoring with home sleep testing, creating a powerful new platform that could redefine neurological diagnostics.

A new Florida venture embeds sleep apnea treatment into cardiology care, a model that could reshape patient outcomes and Vivos Therapeutics' market strategy.

Replacing a controversial task force, Canada's new NACPHS aims to modernize health guidelines with a focus on equity, patient input, and scientific agility.

A new partnership brings NEJM to a physician-only network, challenging AI's grip on medical knowledge and betting on the value of human discussion.

Soaring healthcare costs, fueled by GLP-1 drugs, have employers trapped. A new report shows why flexible benefits are becoming a critical survival strategy.

HOPPR's Catalyst Program is arming global researchers with advanced tools, accelerating AI projects from cancer detection in Africa to risk prediction in the US.

At EHA 2026, Parexel isn't just presenting data; it's unveiling a bold new strategy to fix a broken system and accelerate life-saving blood cancer drugs.

With its pivotal Phase 3 trial complete, Rafael Holdings is on a path to redefine treatment for NPC and transform itself into a commercial-stage biotech.

One in six people globally faces infertility, yet a pervasive stigma silences their struggle. A worldwide movement is now uniting millions to demand change.

A groundbreaking partnership between Servier and n-Lorem Foundation blends pharma R&D muscle with non-profit agility to develop ASO therapies for the rarest of diseases.

Sanofi's promising nerve disease drug fails in late-stage trials, leaving vulnerable patients in limbo and highlighting the brutal realities of medical innovation.

A novel TYK2 inhibitor that can enter the central nervous system has begun human trials, signaling a new frontier for treating diseases like MS and lupus.